Recent Updates
Recently added Catalysts

Lot A of Influenza virus vaccine

Phase 3

Influenza | Monoclonal antibody | Infectious Disease |Novartis AG|Last Updated: May 8, 2012

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment1,507
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00617851Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years OldPHASE3 COMPLETED 1,507Nov 1, 2007Jun 1, 2008May 8, 20122 Dominican Republic
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Geometric Mean Titers (GMTs), by Vaccine Lots
21 days after vaccination

The immunologic equivalence of three consecutive production lots of the influenza virus vaccine was measured in terms of GMTs for all vaccine influenza strains.

Secondary Endpoints
Geometric Mean Titers (GMTs), by Vaccine Group and Strain
21 days after vaccination
Number of Subjects Reporting Solicited Local and Systemic Symptoms
7 days after vaccination
Number of Subjects With at Least One Unsolicited Adverse Event
3 weeks after vaccination
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Influenza virus vaccine (lot A)EXPERIMENTALLot A of the investigational influenza virus vaccine
Influenza virus vaccine (lot B)EXPERIMENTALLot B of the investigational influenza virus vaccine
Influenza virus vaccine (lot C)EXPERIMENTALLot C of the investigational influenza virus vaccine
Influenza virus vaccine (pooled)EXPERIMENTALPooled data of all three lots (Lot A, B and C) of the investigational influenza virus vaccine
Comparator influenza vaccineACTIVE_COMPARATORA US licensed influenza virus vaccine
Interventions
NameTypeDescription
Lot A of Influenza virus vaccineBIOLOGICAL1 injection of the trivalent subunit influenza virus vaccine (lot A) administered intramuscularly
Lot B of Influenza virus vaccineBIOLOGICAL1 injection of the trivalent subunit influenza virus vaccine (lot B) administered intramuscularly
Lot C of Influenza virus vaccineBIOLOGICAL1 injection of the trivalent subunit influenza virus vaccine (lot C) administered intramuscularly
Comparator influenza virus vaccineBIOLOGICAL1 injection of the trivalent subunit influenza virus vaccine administered intramuscularly
All 3 consecutive lots of influenza virus vaccine pooledBIOLOGICAL1 injection of the pooled trivalent subunit influenza virus vaccine administered intramuscularly
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 49 Years
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: * 18 to 49 years of age; * In good health as determined by medical history and physical examination; * Able and willing to provide written informed consent prior to any study procedure; * Able to comply with all study procedures and available for all clinic visits scheduled in t...

Countries:Dominican Republic
Unlock Eligibility Criteria